Bulletin
Investor Alert

London Markets Open in:

Asia Markets Currencies US Market Snapshot

Caribou Biosciences Inc.

NAS: CRBU

GO

Set Alerts

Market Index

Overview Profile Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders
/marketstate/country/us
Caribou Biosciences Inc.

After Hours

 --Quotes are delayed by 20 min

Mar 23, 2023, 7:52 p.m.

CRBU
/zigman2/quotes/228313444/composite

$

4.30

Change

+0.0001 +0.0023%

Volume

Volume 16,074

Quotes are delayed by 20 min

/zigman2/quotes/228313444/composite

Previous close

$ 4.34

$ 4.30

Change

-0.04 -0.92%

Day low

Day high

$4.12

$4.48

Open

52 week low

52 week high

$4.12

$13.19

Open

Company Description

Caribou Biosciences, Inc. engages in the development of an internal pipeline of off-the-shelf CAR-T and CAR-NK cell therapies. Its tools and technologies provide transformative capabilities to basic and applied biological research, therapeutic development, agricultural biotechnology, and industrial ...

Caribou Biosciences, Inc. engages in the development of an internal pipeline of off-the-shelf CAR-T and CAR-NK cell therapies. Its tools and technologies provide transformative capabilities to basic and applied biological research, therapeutic development, agricultural biotechnology, and industrial biotechnology. The company was founded by Jennifer A. Doudna, Rachel E. Haurwitz, Martin Jinek and James Berger on October 28, 2011 and is headquartered in Berkeley, CA.

Valuation

Price to Sales Ratio

27.57

Price to Book Ratio

1.27

Enterprise Value to EBITDA

-0.45

Enterprise Value to Sales

3.35

Total Debt to Enterprise Value

0.17

Efficiency

Revenue/Employee

101,102.00

Income Per Employee

-725,701.00

Receivables Turnover

2.17

Total Asset Turnover

0.03

Liquidity

Current Ratio

9.25

Quick Ratio

9.25

Cash Ratio

8.80

Profitability

Gross Margin

73.71

Operating Margin

-768.17

Pretax Margin

-717.28

Net Margin

-717.79

Return on Assets

-23.97

Return on Equity

-28.87

Return on Total Capital

-29.68

Return on Invested Capital

-27.79

Capital Structure

Total Debt to Total Equity

9.32

Total Debt to Total Capital

8.53

Total Debt to Total Assets

7.30

Long-Term Debt to Equity

8.90

Long-Term Debt to Total Capital

8.14

Officers and Executives

Name Age Officer Since Title
Dr. Rachel E. Haurwitz 35 2011 Founder
Mr. Jason O’Byrne - 2021 Chief Financial Officer
Dr. Steven B. Kanner 61 2017 Chief Scientific Officer
Dr. Syed Rizvi - 2022 Chief Medical Officer
Ms. Ruhi Khan - 2021 Chief Business Officer

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
01/19/2023 Syed Rizvi
Chief Medical Officer 		5,627   Disposition at $6.31 per share. 35,506
12/02/2022 Steven B. Kanner
Chief Scientific Officer 		21,401   Derivative/Non-derivative trans. at $2.69 per share. 57,568
10/06/2022 Ryan Fischesser
VP of Finance and Controller 		2,839   Derivative/Non-derivative trans. at $4.11 per share. 11,668
10/06/2022 Ryan Fischesser
VP of Finance and Controller 		2,839   Derivative/Non-derivative trans. at $2.69 per share. 7,636
10/06/2022 Ryan Fischesser
VP of Finance and Controller 		10,000   Disposition at $10.8 per share. 108,000
09/15/2022 Barbara G. McClung
Chief Legal Officer 		27,518   Derivative/Non-derivative trans. at $2.69 per share. 74,023
09/15/2022 Barbara G. McClung
Chief Legal Officer 		77   Derivative/Non-derivative trans. at $2.69 per share. 207
08/25/2022 Steven B. Kanner
Chief Scientific Officer 		43,248   Disposition at $11.22 per share. 485,242
08/25/2022 Steven B. Kanner
Chief Scientific Officer 		43,248   Derivative/Non-derivative trans. at $2.69 per share. 116,337
08/22/2022 Ryan Fischesser
VP of Finance and Controller 		4,848   Award at $0 per share. 0
05/13/2022 Steven B. Kanner
Chief Scientific Officer 		6,114   Derivative/Non-derivative trans. at $2.69 per share. 16,446
05/13/2022 Steven B. Kanner
Chief Scientific Officer 		68,306   Derivative/Non-derivative trans. at $1.81 per share. 123,633
05/09/2022 Rachel E. Haurwitz
President and CEO; Director 		10,000   Derivative/Non-derivative trans. at $2.96 per share. 29,600
05/05/2022 Ryan Fischesser
VP of Finance and Controller 		1,138   Derivative/Non-derivative trans. at $4.11 per share. 4,677
05/05/2022 Ryan Fischesser
VP of Finance and Controller 		1,136   Derivative/Non-derivative trans. at $2.69 per share. 3,055
03/15/2022 Ryan Fischesser
VP of Finance and Controller 		1,138   Derivative/Non-derivative trans. at $4.11 per share. 4,677
03/15/2022 Ryan Fischesser
VP of Finance and Controller 		1,136   Derivative/Non-derivative trans. at $2.69 per share. 3,055
/news/latest/company/us/crbu

MarketWatch News on CRBU

  3. Gene-Editor Crispr Therapeutics CEO Sees Positive Catalysts Ahead

    4:25 p.m. June 23, 2022

    - Barron's Online

  7. These 3 Funds Invest Like ARK But Didn’t Fall as Far

    12:32 a.m. Feb. 12, 2022

    - Barron's Online

  9. Caribou Biosciences started at outperform with $36 stock price target at Oppenheimer

    8:34 a.m. Dec. 1, 2021

    - Tomi Kilgore

  10. Prime Is the Newest Gene Editing, and It's Getting Better

    7:11 p.m. Oct. 20, 2021

    - Barron's Online

  11. Caribou Biosciences started at buy with $30 stock price target at BofA Securities

    10:23 a.m. Aug. 17, 2021

    - Tomi Kilgore

  12. 7 Companies Open for Trading. Here's How They Did.

    4:58 p.m. July 23, 2021

    - Barron's Online

/news/nonmarketwatch/company/us/crbu

Other News on CRBU

  1. 10-K: CARIBOU BIOSCIENCES, INC.

    6:23 p.m. March 9, 2023

    - Edgar Online - (EDG = 10Q, 10K)

  3. Tradeweb Exchange-Traded Funds Update - September 2022

    1:17 p.m. Oct. 14, 2022

    - Seeking Alpha

  6. Caribou Biosciences (CRBU) Investor Presentation - Slideshow

    9:44 a.m. Sept. 14, 2022

    - Seeking Alpha

  8. Caribou Biosciences (CRBU) Corporate Presentation - Slideshow

    6:39 p.m. Aug. 17, 2022

    - Seeking Alpha

  12. Caribou Biosciences: Potential To Change CAR-T Landscape

    2:19 p.m. Aug. 1, 2022

    - Seeking Alpha

  16. Caribou Biosciences (CRBU) Corporate Presentation - Slideshow

    6:18 p.m. June 10, 2022

    - Seeking Alpha

  18. HYMC, AXLA and EVLO among mid-day gainers

    12:49 p.m. June 10, 2022

    - Seeking Alpha

  21. Loading more headlines...

At a Glance

Caribou Biosciences, Inc.

2929 7th Street

Suite 105

Berkeley, California 94710

Phone

1 5109826030

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2023

View SEC Filings

Revenue

$13.85M

Net Income

$-99.42M

2022 Sales Growth

44.3%

Employees

137.00

Annual Report for CRBU

/news/pressrelease/company/us/crbu

Press Releases on CRBU

  21. Loading more headlines...
Link to MarketWatch's Slice.